-
Atossa Therapeutics Reinforces Z-Endoxifen’s Value Following Priority Review Voucher Program Reauthorization
NASDAQ: $ATOS Atossa Therapeutics, Inc. has underscored the continued strategic significance of its lead drug candidate, Z-Endoxifen, for the treatment of Duchenne Muscular Dystrophy (DMD). This reinforcement comes directly on the heels of recent legislative action by the U.S. Congress to reauthorize the Priority Review Voucher (PRV) program. Z-Endoxifen and the Importance of the PRV…
-
Regenxbio Charts Course for 2026: A Deep Dive into Duchenne Gene Therapy Milestones and Promising Long-Term Data
NASDAQ: $RGNX Biotechnology is often a story of patience, rigorous science, and the relentless pursuit of life-changing therapies. Nowhere is this more evident than in the field of gene therapy, especially concerning devastating conditions like Duchenne Muscular Dystrophy (DMD). Regenxbio, Inc. (NASDAQ: $RGNX) has recently provided a significant update, illuminating a clear roadmap toward crucial…
-
Sarepta Therapeutics Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
NASDAQ: $SRPT Sarepta Therapeutics (NasdaqGS: $SRPT) is at the forefront of innovation in the treatment of Duchenne Muscular Dystrophy (DMD) with its groundbreaking gene therapy, ELEVIDYS. As a rare, progressive genetic disorder, DMD significantly impairs muscle function and can lead to severe health complications. In an effort to provide new hope to affected individuals and…